» Articles » PMID: 8959326

Multiple in Vivo Phosphorylated Tyrosine Phosphatase SHP-2 Engages Binding to Grb2 Via Tyrosine 584

Overview
Date 1996 Dec 1
PMID 8959326
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

SHP-2 (also named PTP1D, syp, or SH-PTP2) has been identified as a phosphotyrosine phosphatase comprising two src-homology-2 (SH2) domains. Upon growth factor stimulation, SHP-2 becomes tyrosine phosphorylated, thereby increasing its catalytic activity. Here, we identified SHP-2 to be phosphorylated on multiple tyrosine residues in response to different stimuli and unmasked the carboxyl-terminal tyrosine 584 as a major phosphorylation site in human cell lines. Tyrosine 584 shares, together with tyrosine 546, the consensus sequence pY-X-N-X, a characteristic of potential binding sites for the SH2 domain of growth factor receptor-bound protein 2 (Grb2). We show here that mutation of tyrosine 584, but not tyrosine 546, to phenylalanine totally abolished the binding of Grb2 to SHP-2. By using a systematic mutagenesis approach, phosphorylation of additional tyrosines in each of the SH2 domains of SHP-2 was detected after coexpression of epidermal growth factor receptor, but not after coexpression of platelet-derived growth factor receptor, whereas tyrosine 263 located in the interspace between SH2 and catalytic domain appears to be exclusively recognized by platelet-derived growth factor receptor. Immunoprecipitation of SHP-2 from a panel of mammary carcinoma cell lines copurifies several tyrosine phosphorylated proteins; the most prominent band has an apparent molecular weight of M(r) 115,000.

Citing Articles

MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.

Rivas S, Marin A, Samtani S, Gonzalez-Feliu E, Armisen R Int J Mol Sci. 2022; 23(22).

PMID: 36430388 PMC: 9697723. DOI: 10.3390/ijms232213898.


From Stem to Sternum: The Role of Shp2 in the Skeleton.

Jensen N, Kelly R, Kelly K, Khoo S, Sidles S, LaRue A Calcif Tissue Int. 2022; 112(4):403-421.

PMID: 36422682 DOI: 10.1007/s00223-022-01042-3.


Targeting SHP2 phosphatase in hematological malignancies.

Kanumuri R, Pasupuleti S, Burns S, Ramdas B, Kapur R Expert Opin Ther Targets. 2022; 26(4):319-332.

PMID: 35503226 PMC: 9239432. DOI: 10.1080/14728222.2022.2066518.


Targeting KRAS in pancreatic cancer: new drugs on the horizon.

Bannoura S, Uddin M, Nagasaka M, Fazili F, Al-Hallak M, Philip P Cancer Metastasis Rev. 2021; 40(3):819-835.

PMID: 34499267 PMC: 8556325. DOI: 10.1007/s10555-021-09990-2.


A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.

Mlakar V, Morel E, Jurkovic Mlakar S, Ansari M, Gumy-Pause F J Exp Clin Cancer Res. 2021; 40(1):189.

PMID: 34103089 PMC: 8188681. DOI: 10.1186/s13046-021-01967-x.